AIMS: Previous work has shown that rifampicin, a potent inducer of several cytochrome P450 (CYP) enzymes and transporters, decreased the plasma concentrations of simvastatin acid by more than 90%. This study was conducted to investigate the effect of rifampicin on the pharmacokinetics of pravastatin. METHODS: In a randomised, cross-over two-phase study with a washout of 4 weeks, 10 healthy volunteers received a 5-day pretreatment with rifampicin (600 mg daily) or placebo. On day 6, a single 40 mg dose of pravastatin was administered orally. Plasma concentrations of pravastatin were measured up to 12 h by a sensitive LC-MS-MS method. RESULTS: During the rifampicin phase, the mean total area under the plasma concentration-time curve of pravastatin [AUC(0-infinity )] was 69% (range 24-220%) of the corresponding value during the placebo phase (P < 0.05, 95% confidence interval for the difference -51.9 - -0.4 ng ml-1.h). In five of the 10 subjects the AUC(0-infinity ) of pravastatin during the rifampicin phase was 50% or less of that during the placebo phase. Rifampicin had no significant effect on the peak concentration, elimination half-life or renal clearance of pravastatin. CONCLUSIONS:Rifampicin caused a statistically significant decrease in the plasma concentration of pravastatin given as a single oral dose to healthy subjects. However, the effect of rifampicin varied greatly between subjects. The mean rifampicin-induced decrease in pravastatin concentration was considerably smaller than that observed previously for simvastatin.
RCT Entities:
AIMS: Previous work has shown that rifampicin, a potent inducer of several cytochrome P450 (CYP) enzymes and transporters, decreased the plasma concentrations of simvastatin acid by more than 90%. This study was conducted to investigate the effect of rifampicin on the pharmacokinetics of pravastatin. METHODS: In a randomised, cross-over two-phase study with a washout of 4 weeks, 10 healthy volunteers received a 5-day pretreatment with rifampicin (600 mg daily) or placebo. On day 6, a single 40 mg dose of pravastatin was administered orally. Plasma concentrations of pravastatin were measured up to 12 h by a sensitive LC-MS-MS method. RESULTS: During the rifampicin phase, the mean total area under the plasma concentration-time curve of pravastatin [AUC(0-infinity )] was 69% (range 24-220%) of the corresponding value during the placebo phase (P < 0.05, 95% confidence interval for the difference -51.9 - -0.4 ng ml-1.h). In five of the 10 subjects the AUC(0-infinity ) of pravastatin during the rifampicin phase was 50% or less of that during the placebo phase. Rifampicin had no significant effect on the peak concentration, elimination half-life or renal clearance of pravastatin. CONCLUSIONS:Rifampicin caused a statistically significant decrease in the plasma concentration of pravastatin given as a single oral dose to healthy subjects. However, the effect of rifampicin varied greatly between subjects. The mean rifampicin-induced decrease in pravastatin concentration was considerably smaller than that observed previously for simvastatin.
Authors: K Sugimoto; M Ohmori; S Tsuruoka; K Nishiki; A Kawaguchi; K Harada; M Arakawa; K Sakamoto; M Masada; I Miyamori; A Fujimura Journal: Clin Pharmacol Ther Date: 2001-12 Impact factor: 6.875
Authors: S A Kliewer; J T Moore; L Wade; J L Staudinger; M A Watson; S A Jones; D D McKee; B B Oliver; T M Willson; R H Zetterström; T Perlmann; J M Lehmann Journal: Cell Date: 1998-01-09 Impact factor: 41.582
Authors: M F Fromm; H M Kauffmann; P Fritz; O Burk; H K Kroemer; R W Warzok; M Eichelbaum; W Siegmund; D Schrenk Journal: Am J Pathol Date: 2000-11 Impact factor: 4.307
Authors: Carl J Fichtenbaum; John G Gerber; Susan L Rosenkranz; Yoninah Segal; Judith A Aberg; Terrence Blaschke; Beverly Alston; Fang Fang; Bradley Kosel; Francesca Aweeka Journal: AIDS Date: 2002-03-08 Impact factor: 4.177
Authors: Manthena V S Varma; Yurong Lai; Bo Feng; John Litchfield; Theunis C Goosen; Arthur Bergman Journal: Pharm Res Date: 2012-05-26 Impact factor: 4.200
Authors: Noton K Dutta; Natalie Bruiners; Michael L Pinn; Matthew D Zimmerman; Brendan Prideaux; Véronique Dartois; Maria L Gennaro; Petros C Karakousis Journal: J Antimicrob Chemother Date: 2016-02-21 Impact factor: 5.790
Authors: Nassr Nassr; Andreas Huennemeyer; Rolf Herzog; Oliver von Richter; Robert Hermann; Manuela Koch; Kevin Duffy; Karl Zech; Gezim Lahu Journal: Br J Clin Pharmacol Date: 2009-10 Impact factor: 4.335
Authors: Judith A Aberg; Susan L Rosenkranz; Carl J Fichtenbaum; Beverly L Alston; Susan W Brobst; Yoninah Segal; John G Gerber Journal: AIDS Date: 2006-03-21 Impact factor: 4.177
Authors: Noton K Dutta; Natalie Bruiners; Matthew D Zimmerman; Shumin Tan; Véronique Dartois; Maria L Gennaro; Petros C Karakousis Journal: J Infect Dis Date: 2020-03-16 Impact factor: 5.226